Du Wei, Chen Chen, Luo Lin-Feng, He Li-Na, Wang Yixing, Zhang Xuanye, Zhou Yixin, Lin Zuan, Hong Shaodong
State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
J Cancer Res Clin Oncol. 2023 Mar;149(3):1103-1113. doi: 10.1007/s00432-022-03978-3. Epub 2022 Mar 18.
The rise of immune checkpoint inhibitors (ICIs) in recent years has coincided with unusual clinical response patterns. Modification of the sum of longest diameters (SLD)-based threshold that reflecting dynamic change of the tumor burden and predicting response to ICIs, may markedly improve current treatment regimens.
The baseline and post-treatment SLD of target lesion was recorded and the maximum percent change of the SLD from baseline was designated as SLD-change score. The optimal cut-off value was obtained using the X-tile program. The relationship between SLD-change score and survival outcome (PFS, OS) was evaluated.
10% cut-off value of SLD-change score was found to be most distinctive for PFS. Responders defined according to this cut-off value showed a significant improvement for PFS and OS. Bone metastasis and brain metastasis were also two independent prognostic factors of PFS and OS, respectively.
10% SLD change score could discriminate for ICIs treatment response, which holds great promise in promoting the development of precise immunotherapeutic strategy.
近年来免疫检查点抑制剂（ICI）的兴起伴随着不寻常的临床反应模式。修改基于最长径总和（SLD）的阈值，该阈值反映肿瘤负荷的动态变化并预测对ICI的反应，可能会显著改善当前的治疗方案。
记录靶病灶的基线和治疗后的SLD，并将SLD相对于基线的最大百分比变化指定为SLD变化评分。使用X-tile程序获得最佳截断值。评估SLD变化评分与生存结果（无进展生存期、总生存期）之间的关系。
发现SLD变化评分的10%截断值对无进展生存期最为显著。根据该截断值定义的反应者在无进展生存期和总生存期方面有显著改善。骨转移和脑转移分别也是无进展生存期和总生存期的两个独立预后因素。
10%的SLD变化评分可区分ICI治疗反应，这在促进精确免疫治疗策略的发展方面具有很大前景。
